Foster Jordan, Corporate Senior Vice President at Charles River, recently spoke with Rapidmicrobiology.com regarding the Accugenix® Microbial ID and Strain typing service.
Low Endotoxin Recovery (LER) has been a topic of interest for almost three years, but not much changed in that time. John Dubczak, General Manager of Charles River's Microbial Solutions, discusses in Outsourced Pharma.
Charles River is set to acquire WIL Research for approximately $585 million in cash, further enhancing the company’s capabilities to include contract development and manufacturing (CDMO).
In an exclusive interview, Cramer spoke with James Foster, chairman, president and CEO of Charles River Labs, the drug testing providers that saw its stock rise over 25% in 2015. In a tough market, Cramer said stocks like Charles River are exactly what investors should be seeking.
During this interview, James Foster shares his enthusiasm for Charles River’s plans to acquire WIL Research.
Charles River Laboratories is planning to hire up to 300 people in the next year in Massachusetts to work in its newly reopened drug safety lab in Shrewsbury. The news comes as the Wilmington-based company bought Ohio-based WIL Research for $585 million in hopes of expanding its drug safety testing capabilities while opening up the opportunity to manufacture pills.
Charles River Laboratories has entered a definitive agreement to acquire WIL Research for approximately $585 million in cash, subject to customary closing conditions. WIL Research provides safety assessment and contract development and manufacturing (CDMO) services to biopharmaceutical, agricultural, and industrial chemical companies globally.
Charles River Laboratories has agreed to acquire WIL Research for approximately $585 million cash, in a deal the buyer said will enhance its global footprint, scientific capabilities, and access to growing market segments.
Charles River Laboratories announced it will pay $585 million in cash to acquire WIL Research Laboratories LLC, a deal that will expand its reach in Europe and provide a toehold in contract manufacturing for biopharmaceutical companies.
Charles River Laboratories extended its run of acquisitions with a $585 million buyout of WIL Research, picking up a company the CRO said will expand its global footprint and bolster its manufacturing capabilities.